Can the genotype or phenotype of two polymorphic drug metabolising cytochrome P450-enzymes identify oral lichenoid drug eruptions?

Journal of Oral Pathology and Medicine

Volumn 39, Issue 6, 2010, Pages 497-505

  Kragelund, C ^a   Hansen, C ^b   Reibel, J ^a   Nauntofte, B ^a   Brosen, K ^c   Jensen, S B ^a   Torpet, L A ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

CYP2C19; CYP2D6; cytochrome P450; genotype; oral lichen planus; phenotype

Indexed keywords

ANALGESIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTIRHEUMATIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRONCHODILATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DECONGESTIVE AGENT; DIURETIC AGENT; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; CYP2C19 PROTEIN, HUMAN; MEPHENYTOIN; SPARTEINE; UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ERUPTION; EXPOSURE; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; LICHEN PLANUS; LICHENOID ERUPTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; POLYPHARMACY; PRIORITY JOURNAL; ALLELE; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DIFFERENTIAL DIAGNOSIS; DRUG INTERACTION; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; PATHOLOGY; QUESTIONNAIRE; URINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; CYTOCHROME P-450 CYP2C19; CYTOCHROME P-450 CYP2D6; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; LICHEN PLANUS, ORAL; MALE; MEPHENYTOIN; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; POLYPHARMACY; QUESTIONNAIRES; SPARTEINE; STATISTICS, NONPARAMETRIC;

EID: 77954357279     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2010.00897.x     Document Type: Article

References (46)

1. Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet 2000 356 : 1587 1591.
2. Thompson DF, Skaehill PA. Drug-induced lichen planus. Pharmacotherapy 1994 14 : 561 571.
3. Chan ES, Thornhill M, Zakrzewska J. Interventions for treating oral lichen planus. Cochrane Database Syst Rev 2000 2 : CD001168.
4. Vargas-Diez E, Garcia-Diez A, Marin A, Fernandez-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol 2005 23 : 285 300.
5. McCartan BE, McCreary CE. Oral lichenoid drug eruptions. Oral Dis 1997 3 : 58 63.
6. Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993 29 : 249 255.
7. Kramer IR, Lucas RB, Pindborg JJ, Sobin LH. Definition of leukoplakia and related lesions: an aid to studies on oral precancer. Oral Surg Oral Med Oral Pathol 1978 46 : 518 539.
8. van der Meij EH, Schepman KP, Plonait DR, Axell T, van dWI. Interobserver and intraobserver variability in the clinical assessment of oral lichen planus. J Oral Pathol Med 2002 31 : 95 8.
9. van der Meij EH, Reibel J, Slootweg PJ, van der Wal JE, de Jong WF, van dWI. Interobserver and intraobserver variability in the histologic assessment of oral lichen planus. J Oral Pathol Med 1999 28 : 274 277.
10. Potts AJ, Hamburger J, Scully C. The medication of patients with oral lichen planus and the association of nonsteroidal anti-inflammatory drugs with erosive lesions. Oral Surg Oral Med Oral Pathol 1987 64 : 541 543.
11. Lamey PJ, McCartan BE, MacDonald DG, MacKie RM. Basal cell cytoplasmic autoantibodies in oral lichenoid reactions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995 79 : 44 9.
12. Bjerrum L, Sogaard J, Hallas J, Kragstrup J. Polypharmacy: correlations with sex, age and drug regimen. A prescription database study. Eur J Clin Pharmacol 1998 54 : 197 202.
13. Kragelund C, Thomsen CE, Bardow A, et al. Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes. Oral Dis 2003 9 : 177 187.
14. Hasler JA, Estabrook R, Murray M, et al. Human cytochromes P450. Mol Aspects Med 1999 20 : 1 137.
15. Bradford LD. CYP2D6 allele rrequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002 3 : 229 243.
16. Tamminga WJ, Wemer J, Oosterhuis B, et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. Eur J Clin Pharmacol 1999 55 : 177 184.
17. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004 9 : 442 473.
18. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004 60 : 329 336.
19. Kragelund C, Hansen C, Reibel J, et al. Polymorphic drug metabolizing CYP-enzymes - a pathogenic factor in oral lichen planus? J Oral Pathol Med 2009 38 : 63 71.
20. Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003 74 : 130 137.
21. Brinn R, Brosen K, Gram LF, Haghfelt T, Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol 1986 22 : 194 197.
22. Flockhart DA. Cytochrome P450 Drug Interaction Table. Version 5.0. Released 12 January, 2009. Available at: http://medicine.iupui.edu/clinpharm/ ddis/table.asp
23. Rasmussen BB, Brix TH, Kyvik KO, Brosen K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002 12 : 473 478.
24. Sanz EJ, Villen T, Alm C, Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clin Pharmacol Ther 1989 45 : 495 499.
25. Vinks A, Inaba T, Otton SV, Kalow W. Sparteine metabolism in Canadian Caucasians. Clin Pharmacol Ther 1982 31 : 23 9.
26. Bock KW, Schrenk D, Forster A, et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994 4 : 209 218.
27. Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997 29 : 1129 1188.
28. Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005 12 : 254 261.
29. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002 13 : 350 365.
30. Sklavounou A, Chrysomali E, Scorilas A, Karameris A. TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. J Oral Pathol Med 2000 29 : 370 375.
31. Fayyazi A, Schweyer S, Soruri A, et al. T lymphocytes and altered keratinocytes express interferon-gamma and interleukin 6 in lichen planus. Arch Dermatol Res 1999 291 : 485 490.
32. Gorski JC, Hall SD, Becker P, Affrime MB, Cutler DL, Haehner-Daniels B. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000 67 : 32 43.
33. Shedlofsky SI, Israel BC, McClain CJ, Hill DB, Blouin RA. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994 94 : 2209 2214.
34. Bergman U, Wiholm BE. Drug-related problems causing admission to a medical clinic. Eur J Clin Pharmacol 1981 20 : 193 200. (Pubitemid 11087485)
35. Guzey C, Spigset O. Genotyping as a tool to predict adverse drug reactions. Curr Top Med Chem 2004 4 : 1411 1421.
36. Thornhill MH, Pemberton MN, Simmons RK, Theaker ED. Amalgam-contact hypersensitivity lesions and oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003 95 : 291 299.
37. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 23 37.
38. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984 36 : 773 780.
39. Guidelines for ATC Classification, 4th edn.
40. Bjerrum L, Rosholm JU, Hallas J, Kragstrup J. Methods for estimating the occurrence of polypharmacy by means of a prescription database. Eur J Clin Pharmacol 1997 53 : 7 11.
41. Zhou S, Gao Y, Jiang W, Huang M, Xu A, Paxton JW. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003 35 : 35 98.
42. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug-herbal interactions. Life Sci 2006 78 : 2146 2157.
43. Mulder H, Herder A, Wilmink FW, Tamminga WJ, Belitser SV, Egberts AC. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice. Pharmacoepidemiol Drug Saf 2006 15 : 107 114.
44. Sachse C, Brockmoller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997 60 : 284 295.
45. McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials 2006 7 : 9.
46. Thorn JJ, Holmstrup P, Rindum J, Pindborg JJ. Course of various clinical forms of oral lichen planus. A prospective follow-up study of 611 patients. J Oral Pathol 1988 17 : 213 218.